Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Single-center, Single-arm Exploratory Clinical Trial to Evaluate the Safety and Efficacy of Fully Human Anti-CD5 Chimeric Antigen Receptor T Cells (CT125A Cells) for the Treatment of Relapsed/Refractory CD5+ Hematopoietic Malignancies

NCT04767308 is registered in ClinicalTrials.gov with Huazhong University of Science and Technology as lead sponsor.

NCT NCT04767308
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04767308 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Single-center, Single-arm Exploratory Clinical Trial to Evaluate the Safety and Efficacy of Fully Human Anti-CD5 Chimeric Antigen Receptor T Cells (CT125A Cells) for the Treatment of Relapsed/Refractory CD5+ Hematopoietic Malignancies
Lead sponsor
Huazhong University of Science and Technology
Phase
Phase 1
Overall status
Unknown status
Start date
March 31, 2021
Completion date
December 31, 2023
Enrollment
18 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

cd5+ relapsed/refractory hematopoietic malignancies, chronic lymphocytic leukemia (cll), diffuse large b-cell lymphoma (dlbcl), follicular lymphoma (fl), mantle cell lymphoma (mcl), peripheral t-cell lymphomas (ptcl)